|
Daily Medical Update
Asthma
Monday, April 13, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Chest (2025) - Practice Guideline
Key Findings
- Seven evidence-based recommendations improve biologic selection for adults with severe asthma by structuring decisions around endotype, biomarkers, comorbidities, lung function, and exacerbation burden.
- The guideline increases emphasis on phenotype-matched biologic prescribing rather than empiric switching, because comparative effectiveness evidence between agents remains limited.
📋 Practice Implication: Use biomarker and comorbidity profiles to choose severe-asthma biologics in adults, and treat the ACCP guideline as the default framework when head-to-head trial data are lacking.
|
Respiratory care (2025) - Systematic Review
Key Findings
- Clinical pathways reduced hospital stay by 0.77 days (95% CI 0.73-0.81) and PICU stay by 0.31 days (95% CI 0.26-0.37) versus standard care.
- Protocols reduced escalation of respiratory support (OR 0.59, 95% CI 0.39-0.59) without improving intubation rates (OR 0.40, 95% CI 0.12-1.34) or noninvasive respiratory support use (OR 1.12, 95% CI 0.76-1.63).
📋 Practice Implication: Standardize pediatric critical asthma management with explicit ED and PICU pathways, because the clearest benefit is shorter stays and less respiratory support escalation rather than lower intubation use.
|
BMC immunology (2025) - Systematic Review
Key Findings
- Depemokimab reduced annualized exacerbations by 0.59 events (95% CI 0.42-0.76) and improved SGRQ quality-of-life scores by 2.93 points (95% CI 0.38-5.48).
- Hospitalization or emergency-department exacerbations fell substantially (RR 0.33, 95% CI 0.15-0.75), while ACQ-5 and pre-bronchodilator FEV1 did not improve significantly.
📋 Practice Implication: Consider depemokimab when the main treatment goal in severe eosinophilic asthma is preventing clinically significant exacerbations, while recognizing that symptom scores and spirometry may move less than event-based outcomes.
|
European respiratory review : an official journal of the European Respiratory Society (2026) - Systematic Review
Key Findings
- Biologics reduced asthma exacerbations by 73% (rate ratio 0.27, 95% CI 0.21-0.34), increased FEV1 by 0.21 L (95% CI 0.11-0.30), and improved ACQ by 0.70 points (95% CI 0.56-0.83).
- Sino-nasal burden also improved, with SNOT-22 reduced by 15.15 points, nasal polyp score by 1.39 points, and Lund-Mackay CT score by 6.64 points, alongside a favorable overall safety profile.
📋 Practice Implication: Escalate earlier to a type 2 biologic when asthma coexists with CRSwNP, because one treatment can materially reduce exacerbations while also improving upper-airway disease burden.
|
Annals of medicine (2026) - Meta-Analysis
Key Findings
- Allergen-specific immunotherapy improved asthma symptoms, reduced medication scores, and improved FEV1 versus control, with all main efficacy outcomes reaching p < 0.001.
- SCIT was more effective than SLIT for symptom improvement, while systemic reactions increased despite no increase in total local side effects.
📋 Practice Implication: For allergic asthma with a clear sensitization target, use immunotherapy as a steroid-sparing adjunct and favor SCIT when greater efficacy justifies the higher systemic reaction burden.
|
|
This asthma update was dominated by high-significance evidence on phenotype-directed biologic care, with strong signals for exacerbation reduction in severe eosinophilic disease and in patients with comorbid chronic rhinosinusitis with nasal polyps. The selected studies also support structured pediatric critical asthma pathways and confirm that allergen immunotherapy can improve symptoms, medication burden, and lung function in allergic asthma. Overall, the most practice-changing evidence this cycle centers on matching advanced therapy to endotype, comorbidity profile, and care setting rather than escalating treatment empirically.
|
|